- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
AAV ProDUCTS & SERVICE
AAV TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap plasmid (retina-validated serotype AAV-RC plasmid)
GeneMedi's AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap plasmid supplies the AAV2 Rep (replication) proteins and the AAV2 variant (Y272F, Y444F, Y500F, Y730F) capsid protein.
You can produce AAV2 variant (Y272F, Y444F, Y500F, Y730F) particle in 293T cell line in high titer using GeneMedi's AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV2 variant (Y272F, Y444F, Y500F, Y730F) vector has been validated in retina (retinal ganglion cells) by both intravitreal injection and sub-retinal injection., with potential applications in retina gene therapy.
Go to AAV
vector system
>>Product Description
| Cat.NO | Product Name | Organization Type | Price(In USD) | ||
|---|---|---|---|---|---|
| P-RC04 | AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid | Academic | 1719 | ||
| P-RC04 | AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-RC04 | AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid |
CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-RC04-Kan | AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid(Kan resistance) |
All | |||
| Currently, GeneMedi only offers amplification services for the Kan-resistant AAV Rep-Cap Plasmids and do not provide seed stocks. | |||||
| P-PK04 | AAV2 variant (Y272F, Y444F, Y500F, Y730F) Vector
System
1. AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug |
Academic | 3024 | ||
| P-PK04 | AAV2 variant (Y272F, Y444F, Y500F, Y730F) Vector
System
1. AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-PK04 | AAV2 variant (Y272F, Y444F, Y500F, Y730F) Vector
System
1. AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-PK04-Kan | AAV2 variant (Y272F, Y444F, Y500F, Y730F) Vector
System(Kan resistance)
1. AAV2 variant (Y272F, Y444F, Y500F, Y730F) Rep-Cap Plasmid(Kan resistance), 10mg 2. AAV Helper Plasmid(Kan resistance), 10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), 10mg |
All | |||
| Currently, GeneMedi only offers amplification services for the Kan-resistant AAV Vector System and do not provide seed stocks. | |||||
| If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | |||||
|
Terms of sale: For Seed (5ug): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party. For plasmid production&lification (≥10mg): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party. |
|||||
Citation
| Title | Publication | Date |
|---|---|---|
| Rhythmic Cilia Changes Support SCN Neuron Coherence in Circadian Clock | Science | 2023/6/2 |
| Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice | Journal of Hepatology | 2022/11/8 |
| MED1 Regulates BMP/TGF-β in Endothelium: Implication for Pulmonary Hypertension | Circulation Research | 2022/10/14 |
| WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy | MOLECULAR CELL | 2022/4/15 |
| E3 ubiquitin ligase RNF5 protects against hepatic ischemia reperfusion injury by mediating PGAM5 ubiquitination | HEPATOLOGY | 2021/11/8 |
| PEG-mediated transduction of rAAV as a platform for spatially confined and efficient gene delivery | Biomaterials Research | 2022/12/2 |
| Loss of CLDN5 in podocytes deregulates WIF1 to activate WNT signaling and contributes to kidney disease | Nature Communications | 2022/3/24 |
| Fibroblast-derived CXCL14 aggravates crystalline silica–induced pulmonary fibrosis by mediating polarization and recruitment of interstitial macrophages | Journal of Hazardous Materials | 2023/9/8 |
| Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer | Autophagy | 2023/8/29 |
| TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling | Journal of Experimental & Clinical Cancer Research | 2023/8/1 |
Validation data
.webp)
Figure. Selected transduction results of AAV2 variant(Y444F) vector system in mouse retina.
Virus and titer: AAV2 variant(Y444F) vector system, 1×1012 vg/ml
Animal: mouse, C57, 2 months
Infection site: retina
Gene delivery method: subretinal cavity injection, 3μl
Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy
Associated products and services
| Products & Service | Products & Service Information |
|---|---|
| AAV Packaging service | Detail |
| Promise-ORF™ viral CDNA library | Detail |
| Plasmid DNA Rapid Preparation Service | Detail |
Facebook
LinkedIn
Twitter
